NASDAQ:CRVO CervoMed (CRVO) Stock Price, News & Analysis $3.95 +0.15 (+3.95%) Closing price 04:00 PM EasternExtended Trading$3.98 +0.03 (+0.76%) As of 07:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About CervoMed Stock (NASDAQ:CRVO) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get CervoMed alerts:Sign Up Key Stats Today's Range$3.81▼$4.1550-Day Range$3.62▼$4.8652-Week Range$3.51▼$13.13Volume60,088 shsAverage Volume39,662 shsMarket Capitalization$36.58 millionP/E RatioN/ADividend YieldN/APrice Target$23.00Consensus RatingModerate Buy Company Overview CervoMed Inc., a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery. The company also develops EIP200 for central nervous system which is in preclinical trials. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts. Read More CervoMed Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks57th Percentile Overall ScoreCRVO MarketRank™: CervoMed scored higher than 57% of companies evaluated by MarketBeat, and ranked 365th out of 859 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingModerate Buy Consensus RatingCervoMed has received a consensus rating of Moderate Buy. The company's average rating score is 2.63, and is based on no strong buy ratings, 6 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialCervoMed has a consensus price target of $23.00, representing about 482.3% upside from its current price of $3.95.Amount of Analyst CoverageCervoMed has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about CervoMed's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for CervoMed are expected to grow in the coming year, from ($2.31) to ($1.98) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of CervoMed is -1.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of CervoMed is -1.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCervoMed has a P/B Ratio of 2.01. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about CervoMed's valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted4.59% of the float of CervoMed has been sold short.Short Interest Ratio / Days to CoverCervoMed has a short interest ratio ("days to cover") of 7.72.Change versus previous monthShort interest in CervoMed has recently decreased by 12.51%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCervoMed does not currently pay a dividend.Dividend GrowthCervoMed does not have a long track record of dividend growth. News and Social Media0.0 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for CervoMed this week, compared to 4 articles on an average week.Search InterestOnly 3 people have searched for CRVO on MarketBeat in the last 30 days. This is a decrease of -80% compared to the previous 30 days. Company Ownership1.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, CervoMed insiders have not sold or bought any company stock.Percentage Held by Insiders35.40% of the stock of CervoMed is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions25.15% of the stock of CervoMed is held by institutions.Read more about CervoMed's insider trading history. Receive CRVO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CervoMed and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CRVO Stock News HeadlinesCervoMed Inc. (NASDAQ:CRVO) Receives Consensus Rating of "Moderate Buy" from AnalystsMay 6 at 2:57 AM | americanbankingnews.comCervoMed (CRVO) Gets a Buy from JonesTradingApril 27, 2026 | theglobeandmail.comI was right about SpaceXJeff Brown predicted Bitcoin before it climbed as high as 52,400%, Tesla before 2,150%, and Nvidia before 32,000%. Now he says SpaceX is shaping up to be the biggest IPO of the decade - and three key milestones just confirmed it. In the past 21 days: SpaceX crossed 10,000 active satellites, Elon filed confidential IPO paperwork with the SEC, and another rocket launched 25 more satellites. Two-thirds of every satellite in orbit now belongs to one company. The public filing could drop any day.May 8 at 1:00 AM | Brownstone Research (Ad)CervoMed Highlights Neflamapimod Progress in Lewy Body DementiaApril 26, 2026 | theglobeandmail.comCervoMed Announces New Data at the 2026 AAN Annual Meeting that Demonstrated Neflamapimod Increased Basal Forebrain Volume and Functional Connectivity in Dementia with Lewy BodiesApril 22, 2026 | globenewswire.comCervoMed Inc. Announces Neflamapimod Clinical Trial Updates and MRI Findings at Lewy Body Dementia Association MeetingApril 7, 2026 | quiverquant.comQCervoMed to Provide Neflamapimod Clinical Program Update and Participate in a Panel on Biomarkers at 2026 Lewy Body Dementia Association Annual MeetingApril 7, 2026 | globenewswire.comCervoMed (CRVO)’s Q4 results feature advancements in its neflamapimod program for dementia Lewy bodies (DLB)March 25, 2026 | msn.comSee More Headlines CRVO Stock Analysis - Frequently Asked Questions How have CRVO shares performed this year? CervoMed's stock was trading at $7.90 at the beginning of the year. Since then, CRVO stock has decreased by 50.0% and is now trading at $3.95. How were CervoMed's earnings last quarter? CervoMed Inc. (NASDAQ:CRVO) posted its quarterly earnings data on Friday, March, 13th. The company reported ($0.88) EPS for the quarter, missing the consensus estimate of ($0.79) by $0.09. The company had revenue of $0.01 million for the quarter, compared to the consensus estimate of $0.84 million. CervoMed had a negative trailing twelve-month return on equity of 96.04% and a negative net margin of 672.80%. How do I buy shares of CervoMed? Shares of CRVO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of CervoMed own? Based on aggregate information from My MarketBeat watchlists, some other companies that CervoMed investors own include Zomedica (ZOM), Jumia Technologies (JMIA), Nano Dimension (NNDM), NVIDIA (NVDA), Broadcom (AVGO), Arista Networks (ANET) and e.l.f. Beauty (ELF). Company Calendar Last Earnings3/13/2026Today5/08/2026Next Earnings (Estimated)5/11/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (3m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 CRVO's financial health is in the Yellow zone, according to TradeSmith. CRVO has been in this zone for over 3 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CRVO Previous SymbolNASDAQ:CRVO CIK1053691 Webdiffusionpharma.com Phone14342200718Fax434-220-0722Employees4Year FoundedN/APrice Target and Rating Average Price Target for CervoMed$23.00 High Price Target$31.00 Low Price Target$11.00 Potential Upside/Downside+482.3%Consensus RatingModerate Buy Rating Score (0-4)2.63 Research Coverage8 Analysts Profitability EPS (Trailing Twelve Months)($2.98) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$26.97 million Net Margins-672.80% Pretax Margin-672.97% Return on Equity-96.04% Return on Assets-82.88% Debt Debt-to-Equity RatioN/A Current Ratio4.91 Quick Ratio4.91 Sales & Book Value Annual Sales$4.01 million Price / Sales9.12 Cash FlowN/A Price / Cash FlowN/A Book Value$1.97 per share Price / Book2.01Miscellaneous Outstanding Shares9,260,000Free Float5,981,000Market Cap$36.58 million OptionableNot Optionable Beta-0.63 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report This page (NASDAQ:CRVO) was last updated on 5/8/2026 by MarketBeat.com Staff. From Our PartnersOne executive order. The biggest wealth transfer of your lifetime.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredYour book attachedYour Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...Profits Run | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredCollect $1,170 a month from silverI've Rarely Seen This With Silver This combination - 20% dividends + 68% share appreciation - never happens...Investors Alley | SponsoredBatten down the hatches – Project Tengu is comingStarting June 16, This AI Lab Could Take Off Dramatically Time magazine recently named this lab "the most d...Chaikin Analytics | SponsoredNobody's Asking Where The SpaceX Money Comes FromWhen SpaceX goes public, fund managers will sell existing portfolio holdings to fund the move. Trillions in as...Americas Gold Company | SponsoredSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CervoMed Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CervoMed With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
